Investigational drug · Phase 3
Obexelimab
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "Obexelimab"
First trial start
2023
Jan 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Obexelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
- Warm Autoimmune Hemolytic Anemia
- Relapsing Multiple Sclerosis
- IgG4 Related Disease
Approved drugs for the same conditions: Anemia · Multiple sclerosis · Lupus (SLE) · Hematology and blood cancers · Neurology · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Obexelimab" as an intervention, largest first.
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseasePivotal-lookingActive, not recruiting
Zenas BioPharma (USA), LLCIndustry
NCT05662241 · 194 participants · Start Jan 9, 2023 · Primary completion Nov 13, 2025
Drug: Obexelimab · For: IgG4 Related Disease
Sites: Stanford, California; Naples, Florida; Atlanta, Georgia · 65 sites in all
- A Study of Obexelimab in Patients With Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Zenas BioPharma (USA), LLCIndustry
NCT06559163 · 190 participants · Start Sep 17, 2024 · Primary completion Sep 23, 2026
Drug: Obexelimab; Placebo · For: Systemic Lupus Erythematosus
Sites: Peoria, Arizona; Fresno, California; Huntington Park, California · 110 sites in all
- A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)Pivotal-lookingActive, not recruiting
Zenas BioPharma (USA), LLCIndustry
NCT05786573 · 134 participants (planned) · Start Sep 25, 2023 · Primary completion Jun 30, 2026
Drug: Obexelimab; Obexelimab · For: Warm Autoimmune Hemolytic Anemia
Sites: Milan, Italy; Gdansk, Poland; Burgos, Spain · 7 sites in all
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)Active, not recruiting
Zenas BioPharma (USA), LLCIndustry
NCT06564311 · 93 participants (planned) · Start Aug 26, 2024 · Primary completion Aug 28, 2025
Drug: Obexelimab; Placebo · For: Relapsing Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 47 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beyond monospecificity in systemic lupus erythematosus: Emerging roles of bispecific and trispecific antibodies.
Negrini S, Nicola S, Brussino L · Lupus 2026
- IgG4-related autoimmune pancreatitis: a journey.
Löhr JM · Pancreatology 2026
- From immune heterogeneity to targeted therapies in IgG4-related disease.
Hara S, Mizushima I, Iwata Y · Curr Opin Rheumatol 2026
- Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease.
Dörner T · N Engl J Med 2026
- Obexelimab for the Treatment of IgG4-Related Disease.
Della-Torre E, Baker MC, Zhang W, et al. · N Engl J Med 2026
- IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.
El-Feghi M, Cornell LD, Geldenhuys L, et al. · Kidney Int Rep 2026
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AfimetoranBMS-986256, BLN-256Phase 32 trials
Beeline Medicines Corporation · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.